Biogen (BUE:BIIB) Buildings And Improvements : ARS0 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Biogen Buildings And Improvements?

Biogen's quarterly buildings and improvements increased from Sep. 2023 (ARS0 Mil) to Dec. 2023 (ARS578,069 Mil) but then declined from Dec. 2023 (ARS578,069 Mil) to Mar. 2024 (ARS0 Mil).

Biogen's annual buildings and improvements increased from Dec. 2021 (ARS171,653 Mil) to Dec. 2022 (ARS267,050 Mil) and increased from Dec. 2022 (ARS267,050 Mil) to Dec. 2023 (ARS578,069 Mil).

Biogen Buildings And Improvements Historical Data

The historical data trend for Biogen's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Buildings And Improvements Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

49,910.96

83,438.91

171,652.70

267,049.68

578,069.30

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	578,069.30	-

Biogen Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.